comprehensive -WSS

comprehensive

author：entertainment 2025-09-29 21:26:33 - browse：51

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： UnitedHealth’s board chair also owns a personal investment firm

WSS

Key House Republican on health care plans exit from Congress

STAT Readout Newsletter: Today's biggest biotech updates

First Opinion Podcast: Long Covid needs a new approach

How digital tools helped lower hypertension in marginalized patients

Industry veterans launch new biotech VC with $310M

FDA gives detailed accounting of AI

explore

comprehensive

Wikipedia

Virginia high school admissions case could be legal follow

Will Ozempic

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UnitedHealth’s board chair also owns a personal investment firm

Wildfire smoke exposes gaps in outdoor worker protections

Doctors' information doesn't help them choose wisely when sick

Continuity nursing helped my family in our darkest PICU moments

FDA warns J&J's Abiomed: We will regulate your software

Tori Bowie and the unacceptable rates of Black maternal death

STAT Summit: GSK CEO on pharma giant's new direction

focus

The Readout: Gilead, Bernie Sanders, and other pharma news

UnitedHealth’s board chair also owns a personal investment firm

Medicare reduced heart disease by changing how it pays doctors

The Readout: Gilead, Bernie Sanders, and other pharma news

What we’ve learned from the Aduhelm mess

STAT Summit: GSK CEO on pharma giant's new direction

explore

focus

explore

focus